Posted by Michael Wonder on 18 Sep 2023
Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab
18 September 2023 - Positive CHMP opinion based on comprehensive package of analytical, pre-clinical and clinical data.
Sandoz today announced that the CHMP of the EMA, has adopted a positive opinion recommending marketing authorisation for their biosimilar trastuzumab (150 mg, for intravenous use), developed by EirGenix.
